ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FAQs About Rydapt (Midostaurin): Understanding Its Uses and Benefits
November 17, 2023The recent approval of Rydapt (Midostaurin) by the FDA has generated a lot of interest and questions regarding this new targeted therapy for acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM). -
Astellas’ Xospata wins FDA nod in AML, with Daiichi competition looming
December 06, 2018On an acute myeloid leukemia (AML) roll, the FDA has green-lighted Astellas’ Xospata, also known as gilteritinib. For Astellas, it marks the first step toward challenging Novartis’ Rydapt and likely just a slim head start against Daiichi Sankyo.
Pharma Sources Insight January 2025
